Rituximab for rapidly progressive juvenile systemic sclerosis.

Area of Science:

• Pediatric Rheumatology
• Immunology
• Systemic Sclerosis Research

Background:

• Juvenile systemic sclerosis (JSSc) with a rapidly progressive course presents a life-threatening challenge with a poor prognosis.
• Rituximab (RTX), a B-cell depleting agent, has emerged as a promising therapeutic option for adult patients with systemic sclerosis (SSc).

Purpose of the Study:

• To evaluate the efficacy of rituximab (RTX) in treating rapidly progressive juvenile systemic sclerosis (JSSc).
• To assess the impact of RTX on cardiac, pulmonary, and cutaneous manifestations in pediatric patients with JSSc.

Main Methods:

• A series of four pediatric patients with rapidly progressive JSSc were treated with RTX (375 mg/m2 intravenously) for at least one year.
• Patients received four annual courses of RTX, alongside low-dose oral prednisone and mycophenolate mofetil (MMF).
• Clinical, laboratory, and functional parameters, including cardiac and pulmonary function tests and the Juvenile Systemic Sclerosis Severity Score (J4S), were monitored.

Main Results:

• All four patients (aged 8-17 years) demonstrated significant improvement in J4S, Raynaud's phenomenon, and cutaneous involvement after one year of RTX treatment.
• Patients with cardiac involvement showed improved myocardial function (left ventricular ejection fraction) and resolution of arrhythmias.
• The patient with severe pulmonary involvement experienced significant improvements in respiratory function, including forced vital capacity, FEV1, and DLCO.
• No major adverse events were reported during the treatment period.

Conclusions:

• The combination of RTX and MMF appears effective in halting the rapid progression of juvenile systemic sclerosis (JSSc).
• RTX represents a potential therapeutic strategy for managing severe, rapidly progressive JSSc in pediatric patients.